Country: Canada
Language: English
Source: Health Canada
DEXLANSOPRAZOLE
APOTEX INC
A02BC06
DEXLANSOPRAZOLE
60MG
CAPSULE (DELAYED RELEASE)
DEXLANSOPRAZOLE 60MG
NASOGASTRIC
15G/50G
Prescription
Active ingredient group (AIG) number: 0152766002; AHFS:
APPROVED
2024-01-25
_APO-DEXLANSOPRAZOLE (Dexlansoprazole Delayed-Release Capsules)_ _Page 1 of 48 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-DEXLANSOPRAZOLE Dexlansoprazole Delayed-Release Capsules Capsule (delayed release), 30 mg and 60 mg, Nasogastric and Oral Proton Pump Inhibitor Apotex Inc. 150 Signet Drive Toronto, Ontario M9L 1T9 Submission Control Number: 268660 Date of Initial Authorization: JUL 12, 2022 Date of Revision: JUN 07, 2023 _APO-DEXLANSOPRAZOLE (Dexlansoprazole Delayed-Release Capsules)_ _Page 2 of 48 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Immune 06/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................................. 2 TABLE OF CONTENTS .................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ...................................................................................... 5 4.1 Dosing Considerations ................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ............................................................ 5 4.4 Administration ...................................................... Read the complete document